- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...

Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company ...

Tsukuba, Japan—Recombinant protein production for pharmaceuticals and other applications often involves infecting plants with bacteria carrying specific genes to accumulate desired proteins in plants.

The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...

Microbial systems offer distinct advantages in protein expression, saving costs and time, and offering well-characterized host genetics and ease of scale-up. 2 However, challenges remain in process ...

Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...

Pharming uses living organisms as bioreactors for cheaper, sustainable drug production, but requires navigating complex IP ...

Stay up to date on the latest science with Brush Up Summaries. Finally, although transgenic animals and mammalian cell culture systems promote optimal expression due to correct protein modifications, ...

PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technologyAgreement includes R&D funding for exploratory work, technology access and, assuming exercise of ...

Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-engineered ...